IPA: ImmunoPrecise Price-to-Revenue Coefficient

Brandmark of ImmunoPrecise (IPA)

Will IT infrastructure modernization and laboratory robotization drive growth for ImmunoPrecise Antibodies (IPA)? High barriers to entry provided by the AI platform and phage display confirm the potential, as illustrated by the GURU.Markets platform chart; meanwhile, the value of 5.40 characterizes this median P/S level. Financial stability is based on technology licensing and payments for preclinical research conducted for pharma behemoths.

ImmunoPrecise Antibodies (IPA): P/S Multiple from 07/04/2022 to 09/04/2025

Analytical breakdowns for ImmunoPrecise Antibodies (IPA)

- market price and analyst price targets:
Stock Quotes immunoprecise.com|IPA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ImmunoPrecise|IPA - Total Company Value
- company book value details:
Net Assets per Share ImmunoPrecise Antibodies|IPA - Book Capitalization|Market-to-Book Ratio immunoprecise.com|IPA - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio ImmunoPrecise Antibodies|IPA - Long-Term Debt to Capital|Short-Term Debt to Capital immunoprecise.com|IPA - Company Debts|Debt to Book Value Ratio ImmunoPrecise|IPA - Company Long-Term Liabilities|Amount of Current Liabilities ImmunoPrecise Antibodies|Interim Coverage Ratio immunoprecise.com
- net income and valuation ratios data:
IPA - Net Profit|Expected Profit ImmunoPrecise Antibodies|IPA - Price to Earnings Ratio|Projected Price to Earnings Ratio immunoprecise.com|IPA - PEG Multiple|Enterprise Value to Operating Income Before Depreciation ImmunoPrecise|IPA - Operating profit EBITDA|Net earnings per share for the last four quarters ImmunoPrecise Antibodies|IPA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months immunoprecise.com|IPA - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year ImmunoPrecise Antibodies
- issuer revenue and sales details:
IPA - Revenue and Sales Volume|Company Future Sales immunoprecise.com|IPA - Price-to-Revenue Ratio|Future Price to Revenue ImmunoPrecise
Fundamental company analysis:ImmunoPrecise Antibodies Ltd (IPA)
Finished products of ImmunoPrecise Antibodies

Assessing the operational resilience of ImmunoPrecise Antibodies (IPA) requires an analysis of the company's market capitalization relative to its annual revenue, which determines the premium paid per unit of sales. By examining the P/S ratio trend, an investor can see how the implementation of AI platforms for sustainable antibody synthesis impacts capitalization, helping to identify asset overvaluation risks or potential business undervaluation in a timely manner.

Who ImmunoPrecise Antibodies competes with

Market Cap to Revenue Tempus AI TEM|P/S Multiple QGEN (Qiagen)|Price-to-Revenue Coefficient Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Corp RNA|CRSP: P/S Multiple|Price to Sales genedx.com (WGS)|Market Cap to Revenue RARE|BEAM: Market Capitalization-to-Revenue Ratio|P/S Multiple SRPT|P/S Multiple Twist Bioscience Corp (TWST)|Price-to-Revenue Ratio 10x Genomics, Inc. TXG|NTLA: Market Cap to Revenue Ratio|STOK: Market Cap to Revenue|BioLife Solutions Inc - Market Cap to Sales Volume|WVE: P/S Multiple|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics Inc) - P/S Multiple|Price-to-Revenue Ratio PRME|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|QURE - Price to Sales|P/S Multiple MGTX (MeiraGTx PLC)|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc. - P/S Multiple|Price-to-Revenue Coefficient ocugen.com OCGN|PACB: P/S Multiple|Price to Sales Benitec Biopharma Inc (BNTC)|Price-to-Revenue Ratio Design Pharma|Rocket Corp (RCKT) - Price-to-Revenue Coefficient|P/S Multiple FDMT|Price-to-Revenue Coefficient lexeotx.com|Price-to-Revenue Ratio Korro Bio KRRO|EDIT (Editas Medicine Inc) - Price-to-Sales Ratio|Silence Therapeutics Inc. - P/S Multiple|PRQR - P/S Multiple|CDXS: P/S Multiple|Market Cap to Revenue Ratio SGMO|Price-to-Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Revenue Ratio MGX (Metagenomi Inc.)|P/S Multiple DTIL|P/S Multiple generationbio.com (GBIO)|P/S Multiple BOLD (Boundless Bio, Inc.)|Price-to-Revenue Coefficient Exicure Inc. (XCUR)|IMNN - Price-to-Revenue Ratio|Phio Pharmaceuticals (PHIO) - Market Cap to Revenue|mustangbio.com (MBIO) - Price-to-Revenue Ratio|Market Cap to Revenue TransCode Therapeutics, Inc.|Market Cap to Revenue BNGO|P/S Multiple adnas.com|Price-to-Revenue Ratio bluebird bio (BLUE)|Omega Therapeutics Inc - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Regulus (RGLS) - Price to Sales|SYRS - Price-to-Revenue Ratio|Price-to-Sales Ratio TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology Inc. - Market Capitalization-to-Revenue Ratio